RE:Still no bad newsThe only material news from today:
CVS Health Corp conducted price review and has decided to exclude certain drugs from its insurance coverage. Some of CXR's drugs were in the mix (Nilandron and Dutoprol).
Does anyone here have an analysis of how these drugs rank amongst Concordia's drug portfolio?
https://www.bloomberg.com/news/articles/2016-08-02/cvs-plans-to-bar-novartis-cancer-drug-from-2017-covered-drugs
‘Hyperinflation Strategy’
“More and more small drug companies are basically putting a hyperinflation strategy in place, hoping no one will notice it,” said Troyen Brennan, CVS’s chief medical officer, in a telephone interview. “Our feeling was we needed to address those relatively specifically.”
Other drugs that CVS will exclude because of huge price increases include Nilandron and Dutoprol from Concordia International Corp., and Zegerid and DexPak from Valeant Pharmaceuticals International Inc.